Cellular senescence mediates fibrotic pulmonary disease

作者：Marissa Schafer, Thomas A. White, Koji Iijima, Andrew J. Haak, Giovanni Ligresti, Elizabeth J. Atkinson, Ann L. Oberg, Jodie Birch, Hanna Salmonowicz, Yi Zhu, Daniel L. Mazula, Robert W. Brooks, Heike Fuhrmann‐Stroissnigg, Tamar Pirtskhalava, Y. S. Prakash, Tamar Tchkonia, Paul D. Robbins, Marie Christine Aubry, João F. Passos, James L. Kirkland, Daniel J. Tschumperlin, Hirohito Kita, Nathan K. LeBrasseur · 发表于：Nature Communications · 年份：2017 · DOI：10.1038/ncomms14532 · 被引用次数：1634 · 研究领域：Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis、Histiocytic Disorders and Treatments、Telomeres, Telomerase, and Senescence

Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by interstitial remodelling, leading to compromised lung function. Cellular senescence markers are detectable within IPF lung tissue and senescent cell deletion rejuvenates pulmonary health in aged mice. Whether and how senescent cells regulate IPF or if their removal may be an efficacious intervention strategy is unknown. Here we demonstrate elevated abundance of senescence biomarkers in IPF lung, with p16 expression increasing with disease severity. We show that the secretome of senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib plus quercetin (DQ), is fibrogenic. Leveraging the bleomycin-injury IPF model, we demonstrate that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered. DQ treatment replicates benefits of transgenic clearance. Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, which can be targeted to improve health and function.